{"id":240,"date":"2025-08-05T09:12:04","date_gmt":"2025-08-05T14:12:04","guid":{"rendered":"https:\/\/globalpharma.mixture.com.co\/?p=240"},"modified":"2025-09-08T10:23:54","modified_gmt":"2025-09-08T15:23:54","slug":"cambio-de-requisitos-para-productos-cosmeticos","status":"publish","type":"post","link":"https:\/\/globalpharma.mixture.com.co\/en\/cambio-de-requisitos-para-productos-cosmeticos\/","title":{"rendered":"Changing Requirements for Cosmetic Products"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Decision 944: The new framework that will transform cosmetic sanitary notifications in the Andean region.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a bid to modernize regional regulations and facilitate trade between countries, <strong>the Andean Community (CAN)<\/strong> approved on <strong>June 24 the Decision 944<\/strong>which redefines the requirements for the Mandatory Health Notification (MHN) of cosmetic products. This update will take effect on <strong>December 17, 2025<\/strong>, marking a milestone for manufacturers, importers, and distributors of cosmetics in <strong>Colombia, Peru, Ecuador, and Bolivia.<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>What Changes with the New Regulation?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>944 amends Article 9 of Decision 833<\/strong>, introducing key improvements that address the current needs of the sector:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\ud83d\udd39 <strong>Unnecessary translations are eliminated<\/strong>: it will no longer be mandatory to submit all technical documentation in Spanish, unless specifically requested by an authority.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\ud83d\udd39 <strong>Greater clarity in requirements<\/strong>: the required information is organized into two blocks general and technical data making it easier to structure the procedures.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\ud83d\udd39 <strong>Labeling flexibility:<\/strong>it will be possible to submit a preliminary version of the label at the time of application, and provide the final version when commercialization begins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\ud83d\udd39 <strong>Legal certainty:<\/strong>ongoing applications must be adapted to the new guidelines, improving the traceability and consistency of the system.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A Firm Step Toward Regional Harmonization<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This change is a <strong>concrete response to the needs of a dynamic sector<\/strong>, which advances with constant innovation and demands clear and functional regulations. With this decision, <strong>the CAN strengthens the technical integration<\/strong> of its member countries and fosters a more efficient regulatory environment for businesses, without compromising consumer safety.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In addition, it provides companies with <strong>a more modern, coherent framework adapted to the current technological context<\/strong>, which is especially beneficial for those operating with private labels, contract manufacturing, or imports.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In <em>Global Pharma<\/em>, we support regulatory updates as a tool for development, competitiveness, and access.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Follow us to stay informed about key regulations impacting the pharmaceutical and cosmetic industries in Latin America.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source:<\/strong> <a href=\"https:\/\/www.invima.gov.co\/sala-de-prensa\/el-invima-anuncia-cambios-en-la-regulacion-sanitaria-de-la-comunidad-andina-con-la\"><strong>https:\/\/www.invima.gov.co\/sala-de-prensa\/el-invima-anuncia-cambios-en-la-regulacion-sanitaria-de-la-comunidad-andina-con-la<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Decision 944: The new framework that will transform cosmetic sanitary notifications in the Andean region.<\/p>","protected":false},"author":1,"featured_media":1322,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[6],"tags":[],"class_list":["post-240","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"_links":{"self":[{"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/posts\/240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/comments?post=240"}],"version-history":[{"count":2,"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/posts\/240\/revisions"}],"predecessor-version":[{"id":265,"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/posts\/240\/revisions\/265"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/media\/1322"}],"wp:attachment":[{"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/media?parent=240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/categories?post=240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globalpharma.mixture.com.co\/en\/wp-json\/wp\/v2\/tags?post=240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}